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Introduction
Cell division relies on the activation of cyclins, which bind
to their catalytic partners, the cyclin-dependent kinases
(Cdks), to induce cell cycle progression from the G0/G1
phase to the S phase and later to initiate mitosis. Cyclin E,
a G1 phase cyclin, has been shown to be overexpressed
in many human cancers [1]. In tumor cells cyclin E can be
deregulated by a number of mechanisms: gene
amplification [2,3], downregulation of p27 [4], and
downregulation of its specific F-box protein Fbw7 (also
called hCDC4), which tags phosphorylated cyclin E for
proteosomal degradation [5–7]. Mutations in hCDC4
were found in breast, ovarian, endometrial [8] and
colorectal cancers [6], and were associated with elevated
levels of cyclin E protein. Moreover, cyclin E over-
expression in breast epithelium predisposes transgenic
mice to neoplasia [9]. A new mechanism of cyclin E
deregulation recently described by our group is the
proteolytic processing of full-length cyclin E at two sites in
the amino-terminus by an elastase-like protease,
independently of proteasome-mediated proteolytic
degradation [10,11].
The predominant 50-kDa isoform of cyclin E, called EL1, is
found in both normal cells and tumor cells, and it is
encoded by an alternative, spliced mRNA that is different
from originally cloned cDNA [11,12]. The EL4 cyclin E
isoform is accounted for by alternative translation at
methionine 46, whereas cleavage at two distinct sites in
the amino-terminus accounts for the two pairs of low-
molecular-weight (LMW) cyclin E isoforms (EL2/3 and
EL5/6). Only tumor cells have the machinery to process
cyclin E into its LMW forms [10]. These LMW isoforms
are nuclear and functionally active because they increase
the progression from G1 to S phase [11].
Overexpression of the LMW forms in immortalized
mammary epithelial cells resulted in decreased doubling
time and increased cyclin E kinase activity [13].
Additionally, overexpression of these hyperactive cyclin E
isoforms in ovarian cells deregulated the G1/S transition
[14]. The prognostic potential of LMW isoforms of cyclin E
was recently demonstrated in a retrospective study of 395
breast cancer patients; the LMW isoforms were found to
be much more powerful predictors of poor outcome than
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were estrogen and progesterone receptor status or levels
of cyclin D1, cyclin D3, and HER2/neu [15]. On multi-
variate analysis, cyclin E was found to be eight times more
predictive of poor prognosis than was nodal status [15].
Recently, we directly assessed the mechanism by which
the LMW forms of cyclin E contribute to breast tumor cell
progression [16]. In this commentary we highlight
biochemical and functional differences between the full-
length and LMW isoforms of cyclin E, which may help to
explain how LMW cyclin E isoforms are strong predictors
of breast cancer mortality. This work provides the link
between the prognostic power of LMW cyclin E isoforms
and their biology in breast cancer.
Low-molecular-weight cyclin E and resistance
to p21 and p27 inhibition
Constitutive overexpression of cyclin E has been shown to
shorten the duration of the G1 phase, to decrease cell
size, and to diminish requirements for growth factors
[12,17]. In addition, cyclin E overexpression has been
shown to be associated with increased resistance to
transforming growth factor-β mediated growth inhibition in
some cell lines [18], delayed response to lovastatin-
induced G1 arrest in NIH3T3 cells [19], and partially
abrogated tamoxifen-induced G1 arrest in MCF-7 cells
[20,21]. The common mediators of these growth inhibitory
signals are Cdk inhibitors, which ultimately inhibit cyclin E
and Cdk2 kinase activity.
To assess the sensitivity of LMW isoforms of cyclin E to
Cdk inhibition, we stably transfected MCF-7 cells with
constructs encoding the full-length and two LMW forms
representing elastase-cleaved variants of cyclin E [16].
Clones with equal levels of cyclin E overexpression (fivefold
greater than the endogenous expression) were selected for
comparison. Cyclin E overexpression led to induction of
p53 and upregulation of p21, which partially abrogated
cyclin E and Cdk2 kinase activity of the full-length form of
cyclin E. Despite having the same levels of protein
overexpression as the full-length form, the LMW forms of
cyclin E had twofold greater associated kinase activity. This
was not due to a defect in p21 or p27 binding, as was
shown by immunoprecipitation followed by Western blot
analysis. This conclusion was further confirmed when we
used the baculovirus expression system, which allowed for
precise control of the expression (i.e. amount) of the
different proteins implicated in the activity of the cyclin E
and Cdk2 complexes. In this system, the IC50 (50%
inhibitory concentration) of p21 required to inhibit the
LMW forms of cyclin E was three to fivefold greater than
that needed to inhibit the full-length form; similar results
were obtained with p27.
In a parallel study using an ovarian cancer cell line model,
our group demonstrated an increased resistance to
lovastatin induced G1 arrest in cells overexpressing the
LMW isoforms of cyclin E, as compared with cells not
expressing these forms, despite the binding of p21 and
p27 to these LMW isoforms [14]. Removing 40–69 amino
acids from the amino-terminus of cyclin E conferred new
functions to these deleted isoforms, which resisted the
action of cell cycle inhibitors and extended the range of
Cdk substrates. Because Cdk inhibitors are the mediators
of antiestrogen-induced cell growth inhibition, these
observations prompted us to explore the role of LMW
cyclin E in antiestrogen resistance.
Low-molecular-weight cyclin E and resistance
to antiestrogen treatment
To decipher the effect of cyclin E overexpression on
antiestrogen sensitivity, the pure antiestrogen ICI 182,780
was added to MCF-7 cells to block estrogen receptor
signaling, and the S phase fraction was measured by flow
cytometry at different times after addition of the drug.
These experiments showed that cells transfected with
LMW cyclin E were more refractory to ICI-induced G1
arrest than were cells transfected with the full-length form
over a 3-day period. This increased resistance was shown
to be due to decreased sensitivity of LMW cyclin E
associated kinase activity to p21 and p27 inhibition.
These experiments confirm that overexpression of full-
length cyclin E results in only a slight decrease in
sensitivity to the growth-inhibiting effects of antiestrogens
[20,21]; these results also demonstrate that LMW cyclin E
overexpression results in sustained resistance.
To corroborate our in vitro data, we tested the hypothesis
that patients with ER positive tumors who were eligible for
adjuvant systemic therapy including hormonal therapy
would not benefit from antiestrogen treatment if their
tumors had high levels of total cyclin E. Among 150 stage
I–III estrogen receptor-positive patients who had high
levels of cyclin E, we found no difference in disease-
specific survival rates between patients receiving
antiestrogen treatment with those not treated with
antiestrogens (P = 0.083, log rank test). This observation
suggests that tumors that greatly overexpress cyclin E are
resistant to the effects of antiestrogen therapy. An
independent study also found that cyclin E is a strong
predictor of endocrine therapy failure in human breast
cancer [22].
Low-molecular-weight cyclin E and genomic
instability
Constitutive overexpression of cyclin E in both
immortalized rat embryo fibroblasts and human breast
epithelial cells induces chromosomal instability without
changing centrosome numbers but while impairing S
phase progression, pointing to possible alterations in the
process of licensing the origins of DNA replication [23].190
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Additionally, the overexpression and appearance of LMW
cyclin E are associated with microsatellite instability in
colorectal carcinomas [24].
In our studies we pinpointed that the LMW forms of
cyclin E and, to a lesser extent, the full-length forms were
the mediators of genomic instability. It should be noted
that in all previous studies [23,24] the form of cyclin E
used was an alternatively spliced cyclin E that did not
give rise to protein products in cell lines or tissues. For
our analysis we used constructs representing the full-
length and the LMW forms of cyclin E. We observed that
although overexpression of cyclin E isoforms increased
the fraction of cells in S phase, it did not decrease the
doubling time of the cells, suggesting an S phase delay.
However, flow cytometry analysis demonstrated a four to
sixfold increase in the percentage of cells with polyploid
DNA. Karyotype analysis revealed a four to sevenfold
increase in the number of chromosome aberrations in
those cells that overexpressed the LMW forms. These
aberrations included multiple chromosomal fragments
and subtelomeric chromatid breaks, resulting in
telomeric associations. In addition, a three to fourfold
increase in the number of polyploid and tetraploid cells
was observed in LMW cyclin E transfectants, most likely
as a result of chromosomal endoreduplication. We also
found a significant correlation (P = 0.0003) between
ploidy and cyclin E protein levels among 331 stage I–III
breast cancer patients. Of patients whose tumors
expressed high levels of cyclin E, the 5-year disease
specific survival rate was significantly lower among those
with polyploid tumors (P = 0.02, log-rank test). These
results suggest that overexpression of the LMW forms of
cyclin E induced genomic instability by promoting
aneuploidy and the formation of structural chromosomal
lesions.
These observations indicate that cyclin E overexpression
interferes with the processes shown to be affected when
cyclin E is deleted in mice, such as occurs in endo-
reduplication and firing of the origin of replication. Cyclin
E1/E2 double knockout mice died during mid-gestation
because of impairment of endoreduplication in the
trophoblast giant cells of the placenta [25]. In addition,
cyclin E null mouse embryonic fibroblasts could not exit
from G0 because of the absence of MCM2 loading on the
origin of replication. Most importantly, cyclin E knockout
mouse embryonic fibroblasts were resistant to oncogenic
transformation, confirming the crucial role played by cyclin E
in tumorigenesis.
The phenotype of the Cdk2 knockout mice, which were
viable and had no developmental defects, also raised
questions about the function of cyclin E independent of
Cdk2 [26,27] and p27 binding [28]. Recent work also
provided a direct link between a genetic mutation in the
CDC4 gene, cyclin E overexpression, and genomic
instability, excluding the implication of other biologic
processes in this phenomenon [6].
Conclusion
In summary, overexpression of LMW cyclin E isoforms in
tumor cells conferred biologic properties that impacted on
the cells’ resistance to cell growth inhibitory signals and
on processes that led to genomic instability, such as DNA
replication and chromosomal segregation. The increased
sensitivity of LMW cyclin E overexpressing cells to
genomic instability could help to explain why these
isoforms are such strong predictors of poor outcome
among patients with node negative, stage I breast cancer.
Once expressed, these forms drive the cells to a more
aggressive phenotype, and their detection at such an early
stage, especially in patients with negative lymph nodes,
could help physicians to make a decision toward more
aggressive treatments. This study implies that estrogen
receptor positive tumors that express high levels of LMW
cyclin E will respond poorly to antiestrogens; thus,
patients with these tumors should be considered for
alternative therapeutic strategies. These data could be
used to find inhibitors of LMW isoforms of cyclin E that
could specifically target and kill tumor cells. We showed in
this study that high levels of LMW cyclin E isoforms not
only can predict failure of endocrine therapy but also are
true prognostic indicators because of their influence on
cell proliferation and genetic instability.
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